Novartis Zelmac DTC Ads To Emphasize Relief Of Abdominal Pain, Bloating
Executive Summary
Consumer ads for Novartis Zelmac will emphasize relief of abdominal pain and bloating in addition to constipation, VP and General Manager-U.S. Operations Kurt Graves suggested during an R&D meeting in Basel, Switzerland Dec. 6.
You may also be interested in...
Novartis Zelmac Trade Name Could Be Changed Following FDA Discussions
Novartis' discussions with FDA regarding use of the trade name Zelmac for the irritable bowel syndrome therapy (tegaserod) may lead to the company launching the product under a different name.
Novartis Zelmac Trade Name Could Be Changed Following FDA Discussions
Novartis' discussions with FDA regarding use of the trade name Zelmac for the irritable bowel syndrome therapy (tegaserod) may lead to the company launching the product under a different name.
SmithKline IBS Research Is One Of Nine Divestments Under FTC Order
SmithKline Beecham is required to divest its rights to Alizyme's irritable bowel syndrome therapy renzapride under the FTC consent order allowing the GlaxoSmithKline merger despite Glaxo's recent withdrawal of Lotronex.